ahlam1399
07-09-2015, 10:37 PM
FDA panel: Lilly cancer drug has positive risk/benefit profile
WASHINGTON (Reuters) - An advisory panel to the U.S. Food and Drug Administration effectively supported approval of Eli Lilly & Co's experimental lung cancer drug necitumumab on Thursday but recommended measures be taken to mitigate the drug's risks.
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/47fb4575/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=CZjlToRWnws:btkFWIIhQRo:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=CZjlToRWnws:btkFWIIhQRo:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=CZjlToRWnws:btkFWIIhQRo:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=CZjlToRWnws:btkFWIIhQRo:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=CZjlToRWnws:btkFWIIhQRo:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/CZjlToRWnws
WASHINGTON (Reuters) - An advisory panel to the U.S. Food and Drug Administration effectively supported approval of Eli Lilly & Co's experimental lung cancer drug necitumumab on Thursday but recommended measures be taken to mitigate the drug's risks.
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/47fb4575/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=CZjlToRWnws:btkFWIIhQRo:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=CZjlToRWnws:btkFWIIhQRo:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=CZjlToRWnws:btkFWIIhQRo:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=CZjlToRWnws:btkFWIIhQRo:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=CZjlToRWnws:btkFWIIhQRo:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/CZjlToRWnws